Currently, selective delivery mechanisms, such as antibody‒drug conjugates (ADCs) and ligand-directed systems, present a viable option to deliver FTH1 inhibitors by recognizing tumor-specific markers, thereby sparing normal cells32. This evidence concerns the gene FTH1 and neoplasm.